TY - JOUR
T1 - Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy with Risk of Heart Failure in African Americans
T2 - The Jackson Heart Study
AU - Pandey, Ambarish
AU - Keshvani, Neil
AU - Ayers, Colby
AU - Correa, Adolfo
AU - Drazner, Mark H
AU - Lewis, Alana
AU - Rodriguez, Carlos J.
AU - Hall, Michael E.
AU - Fox, Ervin R.
AU - Mentz, Robert J.
AU - Defilippi, Christopher
AU - Seliger, Stephen L.
AU - Ballantyne, Christie M.
AU - Neeland, Ian J
AU - de Lemos, James A
AU - Berry, Jarett D
N1 - Funding Information:
Metabolomics. In addition, Dr deFilippi had a patent to US20170234888issued.Dr.Seligerreportedgrantsfrom Roche Diagnostics and personal fees from Abbvie Inc. In addition, Dr Seliger had a patent to “Methods for Assessing Differential Risk of Developing Heart” pending.DrBallantynereportedgrantsandpersonalfees from Roche and Abbott. In addition, Dr Ballantyne had a patent to patent 61721475 ("Biomarkers to Improve PredictionofHeartFailureRisk")filedbyBaylorCollege of Medicine and Roche pending. Dr Neeland reported personal fees from Boehringer Ingelheim/Lilly Alliance and AMRA Medical and grants from Novo Nordisk. DrdeLemosreportedgrantsfromAbbottDiagnostics; personal fees from Abbott Diagnostics, Ortho Clinical Diagnostics,NovoNordisc,Amgen,andRegeneron;and grants and personal fees from Roche Diagnostics. DrBerryreportedgrantsfromAbbottandtheAmerican HeartAssociation.Nootherdisclosureswerereported.
Funding Information:
Funding/Support: This project was funded by the
Publisher Copyright:
© 2018 American Medical Association. All rights reserved.
PY - 2019/1
Y1 - 2019/1
N2 - Importance: African Americans have a higher burden of heart failure (HF) risk factors and clinical HF than other racial/ethnic groups. However, the factors underlying the transition from at-risk to clinical HF in African Americans are not well understood. Objective: To evaluate the contributions of left ventricular hypertrophy (LVH) and subclinical myocardial injury as determined by abnormal high-sensitivity cardiac troponin-I (hs-cTnI) measurements toward HF risk among African Americans. Design, Setting, and Participants: This prospective, community-based cohort study was conducted between July 2016 and September 2018 and included African American participants from Jackson, Mississippi enrolled in the Jackson Heart Study without prevalent HF who had hs-cTnI measurements and an echocardiographic examination at baseline. Participants were stratified into categories based on the presence or absence of LVH and subclinical myocardial injury (category 1: hs-cTnI <4 ng/L in women and <6 ng/L in men; category 2: 4-10 ng/L in women and 6-12 ng/L in men; category 3: >10 ng/L in women and >12 ng/L in men). Main Outcomes and Measures: Adjusted associations between LVH, subclinical myocardial injury, and the risk of incident HF hospitalization were assessed using Cox proportional hazards models. Results: The study included 3987 participants (2552 women [64%]; 240 (6.0%) with LVH; 1003 (25.1%) with myocardial injury) with 285 incident HF events over a median follow-up of 9.8 years (interquartile range, 8.9-10.6 years). In adjusted analyses, higher LV mass and subclinical myocardial injury were independently associated with the risk of HF with a significant interaction between the 2 (Pint < 0.001). The highest risk of HF was noted among individuals with both LVH and myocardial injury (absolute incidence, 35%; adjusted hazard ratio [aHR; vs no LVH and no myocardial injury], 5.35; 95% CI, 3.66-7.83). A significant interaction by sex was also observed. Men with LVH and subclinical myocardial injury had an almost 15-fold higher risk of HF (aHR, 14.62; 95% CI, 7.61-28.10) vs those with neither LVH nor injuries. By contrast, women with this phenotype had a nearly 4-fold higher risk of HF (aHR, 3.81; 95% CI, 2.40-6.85). Conclusions and Relevance: The combination of LVH and subclinical myocardial injury identifies a malignant, preclinical HF phenotype in African Americans with a very high risk of HF, particularly among men. This finding could have implications for future screening strategies that are designed to prevent HF in the population.
AB - Importance: African Americans have a higher burden of heart failure (HF) risk factors and clinical HF than other racial/ethnic groups. However, the factors underlying the transition from at-risk to clinical HF in African Americans are not well understood. Objective: To evaluate the contributions of left ventricular hypertrophy (LVH) and subclinical myocardial injury as determined by abnormal high-sensitivity cardiac troponin-I (hs-cTnI) measurements toward HF risk among African Americans. Design, Setting, and Participants: This prospective, community-based cohort study was conducted between July 2016 and September 2018 and included African American participants from Jackson, Mississippi enrolled in the Jackson Heart Study without prevalent HF who had hs-cTnI measurements and an echocardiographic examination at baseline. Participants were stratified into categories based on the presence or absence of LVH and subclinical myocardial injury (category 1: hs-cTnI <4 ng/L in women and <6 ng/L in men; category 2: 4-10 ng/L in women and 6-12 ng/L in men; category 3: >10 ng/L in women and >12 ng/L in men). Main Outcomes and Measures: Adjusted associations between LVH, subclinical myocardial injury, and the risk of incident HF hospitalization were assessed using Cox proportional hazards models. Results: The study included 3987 participants (2552 women [64%]; 240 (6.0%) with LVH; 1003 (25.1%) with myocardial injury) with 285 incident HF events over a median follow-up of 9.8 years (interquartile range, 8.9-10.6 years). In adjusted analyses, higher LV mass and subclinical myocardial injury were independently associated with the risk of HF with a significant interaction between the 2 (Pint < 0.001). The highest risk of HF was noted among individuals with both LVH and myocardial injury (absolute incidence, 35%; adjusted hazard ratio [aHR; vs no LVH and no myocardial injury], 5.35; 95% CI, 3.66-7.83). A significant interaction by sex was also observed. Men with LVH and subclinical myocardial injury had an almost 15-fold higher risk of HF (aHR, 14.62; 95% CI, 7.61-28.10) vs those with neither LVH nor injuries. By contrast, women with this phenotype had a nearly 4-fold higher risk of HF (aHR, 3.81; 95% CI, 2.40-6.85). Conclusions and Relevance: The combination of LVH and subclinical myocardial injury identifies a malignant, preclinical HF phenotype in African Americans with a very high risk of HF, particularly among men. This finding could have implications for future screening strategies that are designed to prevent HF in the population.
UR - http://www.scopus.com/inward/record.url?scp=85059117598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059117598&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2018.4300
DO - 10.1001/jamacardio.2018.4300
M3 - Article
C2 - 30566191
AN - SCOPUS:85059117598
SN - 2380-6583
VL - 4
SP - 51
EP - 58
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 1
ER -